ultiple sclerosis (MS) is a chronic, debilitating disease of the central nervous system characterized by inflammatory cell infiltration and subsequent demyelination of axonal tracts in the brain and spinal cord. Demyelination interferes with normal signal conduction along neuronal axons, ultimately resulting in a number of clinical symptoms including fatigue, pain, muscle weakness, and visual disturbances (1). Although the exact cause of MS remains elusive, a number of genetic and environmental factors are believed to contribute to MS susceptibility. Epidemiological studies have revealed an unusual geographical gradient for MS, in which MS incidence increases with latitude in both hemispheres (2). One potential explanation for this observation is that MS susceptibility is dependent on exposure to sunlight and the subsequent production of vitamin D (3). Consistent with this hypothesis are the findings that vitamin D supplementation and higher circulating vitamin D levels are associated with a decreased risk for MS (4, 5).
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Vitamin D is obtained either from production in the skin upon exposure to sunlight or through ingestion of foods containing vitamin D. Vitamin D undergoes 2 successive hydroxylation steps to form the active hormone 1␣,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] , which is critical for maintaining a serum calcium level of 9-10 mg/dL for proper bone mineralization and neuromuscular function (6) . A decrease in serum calcium stimulates parathyroid hormone (PTH) secretion from the parathyroid gland, leading to increased production of 1,25(OH) 2 D 3 in the kidney. PTH and 1,25(OH) 2 D 3 act in concert to effect both calcium release from bone and reabsorption of calcium in the kidney. 1,25(OH) 2 D 3 also increases intestinal calcium absorption independent of PTH, thus elevating serum calcium back to normal levels.
In addition to its role in regulating serum calcium levels, vitamin D acts as an important immune system modulator. The vitamin D receptor is present in a number of different immune cell types, including monocytes, macrophages, dendritic cells, and activated T cells (7) (8) (9) . In vitro studies have demonstrated that 1,25(OH) 2 D 3 inhibits T-cell proliferation and decreases the expression of inflammatory cytokines such as IL-2 and IFN-␥ (10, 11) . A number of in vivo studies have demonstrated that 1,25(OH) 2 D 3 can suppress inflammation and autoimmune pathology in a variety of animal models of autoimmune disease, including models for insulin-dependent diabetes mellitus, rheumatoid arthritis, and MS (12) (13) (14) . In the experimental autoimmune encephalomyelitis (EAE) model of MS, 1,25(OH) 2 D 3 has been shown to prevent clinical signs of disease as well as to suppress disease progression (14, 15) . The suppressive effects of 1,25(OH) 2 D 3 appear to be closely linked to calcium. Mice on a higher calcium diet require much lower doses of 1,25(OH) 2 D 3 for disease prevention than those on a low-calcium diet (16) . Moreover, complete prevention of EAE only occurs using doses of 1,25(OH) 2 D 3 that elevate serum calcium concentrations to harmful levels, thus limiting its clinical utility (16) . Studies from our laboratory demonstrate that hypercalcemia independent of 1,25(OH) 2 D 3, prevents EAE in female mice. These results suggest that hypercalcemia, or some factor released under hypercalcemic conditions, may be partially responsible for EAE disease protection (17) .
Hypercalcemia stimulates the release of the peptide hormone calcitonin (CT) from parafollicular cells in the thyroid gland. CT causes a rapid decrease in serum calcium levels by interacting directly with osteoclasts, thereby inhibiting osteoclast-mediated bone resorption. This action has led to the use of CT for the treatment of bone disorders such as osteoporosis and Paget's disease (18) . CT exerts its biological effects by binding to a G protein-coupled receptor and modulating a number of downstream secondary messenger pathways. Although the hypocalcemic effects of CT have been well characterized, the importance of CT in calcium homeostasis under normal conditions has been questioned. For example, mice deficient in CT have normal serum calcium levels (19) . Likewise, postthyroidectomy patients who are deficient in CT do not develop hypercalcemia (20) . However, CT levels during pregnancy and lactation are elevated (21) . Thus, it is likely that CT plays a role in skeletal conservation during times of calcium stress (22, 23) . The CT receptor has been identified on circulating lymphocytes and shows differential expression in response to various cytokines. These observations suggest that CT may play a role in immune system modulation (24, 25) . IL-6, which has been identified in MS brain lesions, causes a marked decrease in CT binding to lymphocytes (25) . Conversely, the anti-inflammatory cytokine TGF-␤ causes a significant increase in CT binding by blood monocytes (26) . A number of in vivo animal models of inflammation have demonstrated that CT treatment has an anti-inflammatory effect (27, 28) . Additional studies in human subjects indicate that CT treatment significantly improves the clinical symptoms of the autoimmune disease rheumatoid arthritis, partially through inhibition of the inflammatory cytokine IL-1 (29, 30) . However, the exact role of CT in the immune system remains unclear.
The anti-inflammatory effects of CT, coupled with the data suggesting that 1,25(OH) 2 D 3 is only effective at preventing EAE under conditions favoring high circulating CT levels, led us to explore the potential therapeutic usage of CT in the EAE model of MS. Our results indicate that mice treated with continuously administered pharmacological doses of CT exhibit a modest decrease in clinical scores. However, when CT is used in combination with 1,25(OH) 2 D 3 , the dual-hormone therapy dramatically suppresses EAE without significantly altering serum calcium levels. These results suggest a potential role for this combination as an MS therapeutic intervention.
Results

CT Treatment Causes a Mild Suppression of EAE.
Treatment of female C57BL/6J mice with 6 g/kg CT per day had no significant effect on any of the EAE clinical parameters tested (Fig. 1A and Table  1 ). Treatment with 60 g/kg CT caused a significant delay in the onset of disease and a slight reduction in disease severity. CT caused a significant drop in serum calcium levels at 6 and 18 h after pump implantation (Fig. 1B) . Serum calcium levels returned to normal within 1 week after pump implantation and remained normal for the duration of the experiment. The maximum dose of CT was reduced from 60 to 5 g/kg per day, because mice maintained on the purified diet were more sensitive to hypocalcemic toxicity than mice given a regular chow diet (unpublished observation). Interestingly, treatment with the combination of 1 ng of 1,25(OH) 2 D 3 and 3 g/kg CT per day caused a significant reduction (P Ͻ 0.01) in disease incidence from 78% in the vehicle group to 47% in the group receiving 3 g/kg CT per day (Table  2) . Additionally, treatment with 3 g/kg CT per day caused a significant reduction in the average clinical scores, peak disease severity, and cumulative disease index (CDI) compared with vehicle ( Fig. 2A and Table 2 ). Increasing the CT dose to 5 g/kg per day also caused a significant suppression of clinical EAE but did not increase the efficacy of treatment. Decreasing the dose of CT to 1 g/kg per day eliminated the protective effect of the combination therapy. Treatment with CT caused a transient reduction of 0.7 mg/dL in serum calcium levels 6 hours after pump implantation, which returned to baseline levels within a week of treatment (Fig. 2B) . Furthermore, serum calcium levels remained in the normal range (9-10 mg/dL) for the duration of the experiment.
CT Lowers the Effective Dose of 1,25(OH)2D3 Required to Suppress EAE.
We next sought to determine if the well-known hypocalcemic effect of CT could prevent hypercalcemia in mice treated with higher, more immunosuppressive 1,25(OH) 2 Average clinical EAE scores were determined in vehicle-and CT-treated mice (n ϭ 9 -12). Ten-week-old female C57BL/6J mice were fed a regular chow diet and were immunized with MOG . Seven days after immunization, pumps containing vehicle, 6, or 60 g/kg per day of salmon CT were implanted s.c. (B) Serum calcium levels (Ϯ SD) were determined at selected time points, including 6 and 18 h after pump implantation. CT caused a transient drop in serum calcium levels. 1, CT treatment initiated and continued for the duration of the experiment. * , P Ͻ 0.05 compared with vehicle group. Experiments were performed as described in Fig. 1 . The clinical data demonstrate the mean Ϯ SD from one representative of 3 individual experiments. The cumulative disease index (CDI) was calculated by summing the daily clinical scores and dividing by the number of mice in each group as described in Materials and Methods. * , P Ͻ 0.05 compared to the vehicle group. There were no significant differences in any of the disease parameters measured between the 2 vehicle-treated groups maintained on different levels of dietary calcium ( Fig. 4A and Table 4 ). Mice maintained on the 1.0% calcium diet treated with 1 ng of 1,25(OH) 2 D 3 ϩ CT showed a dramatic suppression of clinical EAE signs compared with the vehicle-treated groups and the 0.25% dietary calcium group that received the same treatment. Furthermore, complete disease prevention occurred in mice maintained on the 1.0% calcium diet and treated with 5 ng of 1,25(OH) 2 D 3 ϩ CT compared with a 60% disease incidence rate in the 0.25% calcium diet group receiving the same treatment (Fig. 4B) . Although the animals treated with 5 ng of 
Discussion
Our results demonstrate that treatment with pharmacological doses of CT cause a modest suppression of EAE. Comparing the slight suppressive effect exerted by CT with the complete prevention of disease in hypercalcemic mice from previous studies clearly indicates that CT is not the sole factor responsible for prevention of EAE under hypercalcemic conditions. Consistent with previous reports, CT treatment caused a transient decrease in serum calcium levels, which returned to baseline levels within 48 h (31) . The transient nature of the hypocalcemic effect by CT has been attributed to down-regulation of the CT receptor by CT itself (32) . Surprisingly, when CT was delivered in combination with a subtherapeutic dose of 1,25(OH) 2 D 3 , it significantly enhanced the suppression of EAE by 1,25(OH) 2 D 3 . Importantly, after the transient decrease at the start of CT treatment, serum calcium levels remained in the normal range for the duration of the experiment. Therefore, with CT present, dramatic suppression of EAE was achieved without hypercalcemia and the therapeutic dose of 1,25(OH) 2 D 3 was reduced. Further research will be needed to elucidate the mechanism through which CT is acting synergistically with 1,25(OH) 2 D 3 to suppress EAE. One potential explanation for this synergism is that CT is causing increased production of endogenous 1,25(OH) 2 D 3 . CT has been shown to increase expression of the 1␣-hydroxylase enzyme that is responsible for converting 25(OH)D 3 to the active hormone 1,25(OH) 2 D 3 (33, 34) . Elevated 1␣-hydroxylase expression by CT, leading to increased endogenous 1,25(OH) 2 D 3 production, could be responsible for the synergistic effect on EAE. Another potential explanation is that CT has the ability to enhance the suppressive effect of certain immunomodulatory agents. A recent study demonstrated a similar synergistic effect by CT and a corticosteroid in an animal model of rheumatoid arthritis. Mice treated with CT and a subtherapeutic dose of prednisolone showed a dramatic reduction in inflammation and attenuation of disease (35) . This suggests that the synergistic effect by CT may be more general, and CT could potentially enhance the ability of several immunosuppressive agents to suppress a number of autoimmune diseases.
Although the combination therapy significantly suppressed clinical signs of EAE beyond subtherapeutic doses of 1,25(OH) 2 D 3 alone, it did not completely prevent EAE unless the animals were hypercalcemic. Furthermore, similar to 1,25(OH) 2 D 3 treatment alone, the combination therapy was much more effective at suppressing disease when the animals 2D3 and CT (n ϭ 5-10). Eight-week-old female C57BL/6J mice were fed 0.25%-calcium-or 1.0%-calcium-purified diet containing 0, 1, or 5 ng of 1,25(OH) 2D3 per day. Two weeks after changing the diet, the mice were immunized with MOG 35-55. Ten days after immunization, pumps delivering either vehicle or 3 g/kg per day of salmon CT were implanted s.c. (B) Serum calcium levels (Ϯ SD) were measured by atomic absorption spectroscopy at selected time points. 1, CT treatment initiated and continued for the duration of the experiment. * , P Ͻ 0.05 compared with both vehicle-treated groups. Experiments were performed as described in Fig. 3 . The clinical data demonstrate the mean Ϯ SD from one representative of 2 individual experiments.
* , P Ͻ 0.05 compared to 0 ng 1,25D3 ϩ vehicle. ** , P Ͻ 0.05 compared to all three vehicle groups. were maintained on a high-calcium diet. 
Materials and Methods
Animals and Diet. Six-week-old female C57BL/6J mice were purchased from Jackson Laboratory. All mice were housed at the University of WisconsinMadison Department of Biochemistry animal facility under specific pathogenfree conditions and exposed to 12-h light-dark cycles. Before administration of experimental diets, mice were fed standard rodent Labdiet 5008 chow (Purina Mills International). For the indicated experiments, 7-8-week-old mice were switched to a purified diet containing all the essential nutrients for normal growth (40) . 1,25(OH) 2D3 (Sigma-Aldrich Fine Chemicals) was added to the purified diet at doses ranging from 0 -5 ng/d based on the average daily consumption of 4 g per mouse. The diet was delivered in solidified agar form 3 times per week beginning 2 weeks before immunization and continued until the termination of the experiment. Animal protocols were approved by the Institutional Animal Care and Use Committee.
Induction of EAE.
Myelin oligodendrocyte glycoprotein peptide (MOG (MEVGWYRSPFSRVVHLYRNGK) was synthesized at the University of Wisconsin-Madison Biotechnology Center using standard Fmoc chemistry and purified to Ն95% by RP-HPLC. The MOG peptide was resuspended in sterile PBS to a concentration of 4 mg/mL and then emulsified with an equivalent volume of complete Freund's adjuvant (CFA) supplemented with 5 mg/mL Mycobacterium tuberculosis H37Ra (DIFCO Laboratories). EAE was induced in 9 -10-week-old female C57BL/6J mice by s.c. injection of 100 L of MOG35-55/ CFA homogenate delivering 200 g of MOG35-55 peptide. On the day of immunization and 48 h later, mice were injected i.p. with 200 ng of pertussis toxin (List Biological Laboratories) diluted in PBS. Mice were scored daily for clinical signs of EAE using the following scale: 0 ϭ no clinical disease, 1 ϭ loss of tail tone, 2 ϭ unsteady gait, 3 ϭ hind limb paralysis, 4 ϭ forelimb paralysis, 5 ϭ death.
Delivery of CT. Salmon CT was purchased from Bachem and resuspended to a concentration of 1 mg/mL in a vehicle containing 150 mM NaCl, 1 mM HCl, and 2% (vol/vol) heat-inactivated sera from female C57BL/6J mice. Model 1002 micro-osmotic pumps (Durect Corporation) were used to deliver CT continuously at an average rate of 0.24 L/h for a total of 14 days. One day before pump implantation, mice were weighed to determine the proper CT dose. Pharmacological doses ranged from 0 -60 g/kg per day depending on the experiment, and the pump reservoirs were filled with either vehicle or CT. The pumps were placed in sterile PBS and primed overnight at 37°C. Seven to 10 days after immunization, pumps were implanted s.c. in the upper back of mice anesthetized with isoflurane. Successful delivery of CT was determined by measuring the liquid volume remaining in the pump reservoir at the termination of the experiment. Serum Calcium Analysis. Blood was collected at selected time points during the experiments. Blood samples were spun at 2,938 g for 15 min, followed by a second spin at 16,883 g for 1 min. Serum calcium levels were determined by diluting 25 L of serum in 975 L of 0.1% LaCl3 and analyzed with a model 3110 Perkin-Elmer atomic absorption spectrometer.
Data Analysis. Individual mice were scored daily, and the mean clinical score Ϯ SD was calculated for each group. Average onset and severity were calculated in affected mice displaying a clinical score of Ն1.0 for a minimum of 2 consecutive days. Onset was calculated by averaging the first day when clinical signs appeared. Severity was determined by averaging the maximum disease score reached during the entire experiment. The CDI was calculated by summing the daily clinical scores for each group for all time points divided by the number of mice per group. Because the duration of each experiment was different, the CDIs from different experiments cannot be directly compared. Statistical analysis was performed using the two-tailed Fisher exact probability test for incidence rates and the unpaired Student's t test for all other measurements. A value of P Ͻ 0.05 was considered statistically significant.
